{
    "id": 15205,
    "fullName": "TRIM24 - RET",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TRIM24-RET results from the fusion of TRIM24 and RET (PMID: 24296167). TRIM24-RET has been identified in thyroid cancer (PMID: 24296167), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 4108,
                    "pubMedId": 24296167,
                    "title": "Central role of RET in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24296167"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8805,
        "geneSymbol": "TRIM24",
        "terms": [
            "TRIM24",
            "hTIF1",
            "PTC6",
            "RNF82",
            "TF1A",
            "TIF1",
            "TIF1A",
            "TIF1ALPHA"
        ]
    },
    "variant": "TRIM24 - RET",
    "createDate": "12/13/2015",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 15131,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib) followed by Tagrisso (osimertinib) with partial response for 13 months, EGFR E746_A750del, T790M, and TRIM24-RET were identified in post-progression tumor samples (PMID: 29883838).",
            "molecularProfile": {
                "id": 30776,
                "profileName": "TRIM24 - RET EGFR E746_A750del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12672,
                    "pubMedId": 29883838,
                    "title": "Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29883838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19914,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tagrisso (osimertinib) and was found via cell free DNA testing to harbor an EGFR exon 19 deletion, TRIM24-RET, and RB1 R7fs (PMID: 31300450).",
            "molecularProfile": {
                "id": 34672,
                "profileName": "TRIM24 - RET EGFR exon 19 del RB1 R7fs"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15468,
            "profileName": "TRIM24 - RET",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30776,
            "profileName": "TRIM24 - RET EGFR E746_A750del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34671,
            "profileName": "TRIM24 - RET RB1 R7fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34672,
            "profileName": "TRIM24 - RET EGFR exon 19 del RB1 R7fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}